
    
      The primary purpose of this study is to determine if treatment with ramucirumab causes
      prolongation of the QTc/QT interval in participants with advanced cancer, to assess the
      safety and tolerability of ramucirumab therapy, and to evaluate the pharmacokinetic (PK)
      characteristics of ramucirumab
    
  